Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FHTX

FHTX - Foghorn Therapeutics Inc Stock Price, Fair Value and News

$4.76-0.41 (-7.93%)
Market Closed

25/100

FHTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

25/100

FHTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FHTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FHTX Price Action

Last 7 days

-11.7%

Last 30 days

7.7%

Last 90 days

-17.5%

Trailing 12 Months

12%

FHTX RSI Chart

FHTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FHTX Valuation

Market Cap

279.4M

Price/Earnings (Trailing)

-3.76

Price/Sales (Trailing)

9.04

EV/EBITDA

-3.36

Price/Free Cashflow

-3.24

FHTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FHTX Fundamentals

FHTX Revenue

Revenue (TTM)

30.9M

Rev. Growth (Yr)

223.77%

Rev. Growth (Qtr)

13.42%

FHTX Earnings

Earnings (TTM)

-74.3M

Earnings Growth (Yr)

-11.17%

Earnings Growth (Qtr)

-36.8%

FHTX Profitability

EBT Margin

-280.24%

Return on Equity

68.48%

Return on Assets

-37.51%

Free Cashflow Yield

-30.83%

FHTX Investor Care

Shares Dilution (1Y)

5.55%

Diluted EPS (TTM)

-1.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202523.5M24.2M24.5M30.9M
202433.9M35.2M25.5M22.6M
202320.6M21.7M32.6M34.2M
20225.0M9.2M15.8M19.2M
2021652.3K874.5K1.1M1.3M
2020000430.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Foghorn Therapeutics Inc

FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://foghorntx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES161

Foghorn Therapeutics Inc Frequently Asked Questions

FHTX is the stock ticker symbol of Foghorn Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Apr 29 2026, market cap of Foghorn Therapeutics Inc is 279.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Apr 29 2026, FHTX's PE ratio (Price to Earnings) is -3.76 and Price to Sales (PS) ratio is 9.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FHTX PE ratio will change depending on the future growth rate expectations of investors.